Have an area of the central 5 mm zone of cornea affected, presence of at least one clinical sign observed by slit-lamp examination with white light and/or cobalt blue light, fluorescein, and a Wratten filter, and at least one clinical sign observed with AS-OCT.
If dosing with Acthar at time of Screening Visit, must have a history of stable dosing for approximately 8 weeks, plan to maintain the same Acthar treatment dose and regimen, and have demonstrated little to no improvement in severity of LSCD.
Sponsor written confirmation of qualifying LSCD diagnosis.
Inflammation associated with LSCD or other non-infectious inflammation that will not interfere with subject's participation.
You may not be if
Any active ocular infection (bacterial, viral, fungal, or protozoan) in either eye.
Ocular surgery within 30 days of Day 0 where investigator assesses that healing is not considered complete/stable.
Planned ocular surgery on or before Week 20 visit.
Presence or history of any ocular or systemic disorder, condition, or procedure that might hinder the efficacy of the study treatment or its evaluation, or could interfere with the interpretation of study results, in the opinion of the investigator.
